Key Points
- CFO Jerome Wong purchased 1,308 shares on March 16 at $11.85 each for $15,499.80, raising his holding to 4,184 shares (a 45.48% increase) and disclosing the trade in an SEC filing.
- Wall Street analysts have a consensus rating of "Reduce" on Ekso Bionics with an average target price of $6.00, reflecting mixed notes (one Hold, one Sell) and recent downgrades.
- Ekso Bionics has a market capitalization of $37.52 million; the stock opened at $10.54 and sits within a 52‑week range of $2.73 to $13.50, with 50‑day and 200‑day moving averages of $9.95 and $6.79 respectively.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO - Get Free Report) CFO Jerome Wong purchased 1,308 shares of the stock in a transaction on Monday, March 16th. The stock was bought at an average price of $11.85 per share, for a total transaction of $15,499.80. Following the completion of the transaction, the chief financial officer directly owned 4,184 shares of the company's stock, valued at approximately $49,580.40. This trade represents a 45.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Ekso Bionics Stock Performance
Ekso Bionics stock opened at $10.54 on Friday. The firm has a market capitalization of $37.52 million, a P/E ratio of -2.05 and a beta of 0.79. The stock has a fifty day moving average price of $9.95 and a two-hundred day moving average price of $6.79. Ekso Bionics Holdings, Inc. has a 52-week low of $2.73 and a 52-week high of $13.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.63 and a quick ratio of 1.07.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the stock. HC Wainwright cut shares of Ekso Bionics from a "buy" rating to a "neutral" rating in a research report on Wednesday, December 31st. Wall Street Zen raised shares of Ekso Bionics to a "hold" rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ekso Bionics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Ekso Bionics has a consensus rating of "Reduce" and an average target price of $6.00.
Get Our Latest Stock Analysis on Ekso Bionics
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of EKSO. Consolidated Portfolio Review Corp acquired a new stake in shares of Ekso Bionics in the 3rd quarter valued at $333,000. Geode Capital Management LLC lifted its stake in shares of Ekso Bionics by 68.9% during the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company's stock valued at $218,000 after acquiring an additional 10,281 shares during the period. Citadel Advisors LLC bought a new position in Ekso Bionics in the third quarter valued at about $198,000. Shay Capital LLC bought a new position in Ekso Bionics in the third quarter valued at about $67,000. Finally, Virtu Financial LLC acquired a new stake in Ekso Bionics in the third quarter worth about $57,000. 6.42% of the stock is currently owned by institutional investors.
Ekso Bionics Company Profile
(
Get Free Report)
Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.
In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
